Given the emerging data of MajesTEC-3, here is a table of early BCMA based therapies (combination BCMA (Tec-Dara, Belnrep triplet) and Cilta Cel #ASH25 #mmsm @ASH_hematology Efficacy summary

Looking forward to seeing the data on teclistamab and daratumumab in MajesTEC-3 presented at #ASH25 by @mvmateos @End_myeloma . The study population of 1-3 prior lines, prior PI and IMiD, and control arm of dara pom dex or dara Vel dex is similar to CARTITUDE-4 with cilta-cel

INCREDIBLE #ASH25 LBA by @mvmateos @End_myeloma et al. bsAbs stealing the show across #MMsm LoT! As we all admire MajesTEC-3 PFS HR, I'll add the key reason IMO this was possible: Q4W tec dosing & primary IVIG PPx. Fewer Gr3+ infxns ➡️ stay on bsAb/CD38 longer ➡️ victory 👏

Dex for management of CRS assoc w/ talquetamab [GPRC5D-targeting bispecific antibody (bsAb)] in Pts w/ RRMM [Nov 3, 2025] McElwee et al. #ASH25 abs25-14627 PID 720 https://t.co/L0BCnUjue9 #mmsm #SuppOnc

You may know us as LLS. Or more formally, The Leukemia & Lymphoma Society. Now, we’ve officially changed our name to Blood Cancer United. It’s a name we chose very carefully to better represent who we are and who we serve—anyone affected by any blood cancer. ❤️ There’s strength

2/ In particular: the more chemo ("CTX") drugs in any given bridging regimen, the worse & more persistent the post-CAR-T cytopenias. Also clear signal toward ⬆️ serious infections as well, which can drive #MMsm NRM. Talq bridging may be a winner here! https://t.co/loX9iMpTpm

🎉Finally out🎉 Talquetamab bridging is feasible, safe and effective allowing rapid disease control with minimal grade toxicity @BloodPortfolio https://t.co/QjnrOamEFo #mmsm

1/ Our call to action is out in @BloodAdvances! Title speaks for itself. Given concerningly high infection risk with bsAbs in myeloma #MMsm, IVIG/SCIG should be started regardless of any IgG threshold. Global authors & global audience, including insurance & healthcare funders.

1/ 🚨 NEW STUDY: Real-world data on sequential BCMA CAR-T therapy in RRMM patients using 💉ide-cel followed by 💉cilta-cel. First of its kind! Safe, feasible, and effective in heavily pretreated patients. Let’s dive in ⬇️ #MultipleMyeloma #CART #HemeTwitter #mmsm #MedEd #myeloma

The ❓ at ODAC matters! (shout out to recent @WolverHeme pod ep discussing the recent STARGLO and AQUILA- based decisions).. if the ❓ is about the “favorability of the proposed dosage”, makes sense that it’s going to be a no… but it still should be an option for patients IMO

Bispecifics in lymphoma? Great! Adding chemo?? Even better!! Check out a review of this new combo! 🤓@Warrick_PharmD @HOPArx #OncoPharm https://t.co/a0PP0y06gK

Our model demonstrates feasibility and safety of outpatient administration for BsAb step-up dosing with appropriate patient selection, multidisciplinary collaboration and prophy toci! @WinshipAtEmory @SagarLonialMD @AjayNookaMD https://t.co/v4BaEwenb4

Check out the latest WolverHeme episode featuring delicious 🍻 and a lively discussion with a great crew of folks! ps... @VictoriaNachar and I talk about our new paper #mmsm 🤓

Check out are latest episode, with a star-studded cast! 🤩 "Dex and the Cytokine City: Managing CRS with Bispecifics" #leusm #lymsm #myeloma #TwitteRx @berninini @thisisJamesD @VictoriaNachar @ajperissinotti @PharmacistOnc

Excited to speak to my PharmD colleagues at @HOPArx 2025! Should we really be bending clinical trial schemas in myeloma to optimize outcomes for our patients? ... Yes. Join @thisisJamesD #brookepeters and me on Fri 4/11 morning as we discuss why! #MMsm #downwithdex

#iwGPRC5D2025 thanks @szusmani @VJHemOnc for organizing this! Lots of unknowns about managing skin/nail toxicities with talquetamab in #MMsm. My list here, but more prospective research needed in racially diverse settings - early awareness (by pts & team) & PPx steps are key!

Dexamethasone for CRS with teclistamab in R/R Multiple Myeloma - @thisisJamesD https://t.co/Q27LAqbwGH #OncoDaily #Oncology #Cancer #Health #Medicine #MultipleMyeloma #MedTwitter #MedEd #MedOnc #MedNews

#DownWithDex... except for CRS! @RahulBanerjeeMD @thisisJamesD

🌶️Hot off the press! 🌶️ Dexamethasone for CRS with teclistamab. You don't need toci for grade 1 CRS! great team work - @VictoriaNachar @CWagnerPharmD @kczmj @KLratermann @MikhailaPharmD @KG_PharmD @khouri_jack https://t.co/lxpTdhkQie

In lieu of a head-to-head trial comparing ide-cel and cilta-cel (which we will never get), check out our study in @JCO_ASCO comparing these products in over 600 patients. congrats #DorisHansen @DrKrinaPatel @SurbhiSidanaMD @DimaDanai @CWagnerPharmD https://t.co/kuNHUMwxEo